Haploinsufficient autosomal dominant diseases are due to heterozygous mutations that cause inadequate protein expression. Compounds that increase expression of the wild-type allele would be one strategy for treating patients. Synthetic antisense oligonucleotides and double-stranded RNAs have the potential to increase gene expression, making them starting points for drug development. Our goal is to outline strategies for using synthetic nucleic acids to enhance gene expression. We discuss the strengths and limitations of these strategies and the practical challenges behind upregulating the expression of genes as a treatment for haploinsufficient autosomal dominant diseases.
EgliM, ManoharanM. Chemistry, structure and function of approved oligonucleotide therapeutics. Nucleic Acids Res, 2023; 51:2529–2573; doi: 10.1093/nar/gkad067
2.
HofmanCR, CoreyDR. Targeting RNA with synthetic oligonucleotides: Clinical success invites new challenges. Cell Chem Biol, 2024; 31:125–138; doi: 10.1016/j.chembiol.2023.09.005
3.
VinjamuriBP, PanJ, PengP. A review on commercial oligonucleotide drug products. J Pharm Sci, 2024; 113:1749–1768; doi: 10.1016/j.xphs.2024.04.021
4.
SyedYY. Donidalorsen: First approval. Drugs, 2025; doi: 10.1007/s40265-025-02257-y
5.
WhalenS, HéronD, GaillonT, et al.Novel comprehensive diagnostic strategy in pitt-hopkins syndrome: Clinical score and further delineation of the TCF4 mutational spectrum. Hum Mutat, 2012; 33:64–72; doi: 10.1002/humu.21639
6.
GoodspeedK, Pérez-PalmaE, IqbalS, et al.Current knowledge of SLC6A1-related neurodevelopmental disorders. Brain Commun, 2020; 2:fcaa170; doi: 10.1093/braincomms/fcaa170
TillerJ, DeLeeuwMB, KangJQ, et al.SLC6A1 patient & organization perspective: Founding of SLC6A1 connect, research, and ongoing efforts. Ther Adv Rare Dis, 2024; 5:26330040241283734; doi: 10.1177/26330040241283734
9.
de BreukA, HeesterbeekTJ, BakkerB, et al.Evaluating the occurrence of rare variants in the complement factor H gene in patients with early-onset Drusen Maculopathy. JAMA Ophthalmol, 2021; 139:1218–1226; doi: 10.1001/jamaophthalmol.2021.4102
10.
MeshkovAN, ErshovaAI, KiselevaAV, et al.The prevalence of heterozygous familial hypercholesterolemia in selected regions of the Russian Federation: The FH-ESSE-RF Study. J Pers Med, 2021; 11:464; doi: 10.3390/jpm11060464
11.
MostazaJM, MartinezI, GamesJM, et al.EE637 Cost of follow-up in patients with heterozygous familial hypercholesterolemia in Spain: Results from the reality study. Value Health, 2022; 25:S181; doi: 10.1016/j.jval.2022.09.876
12.
GrothKA, HoveH, KyhlK, et al.Prevalence, incidence, and age at diagnosis in Marfan Syndrome. Orphanet J Rare Dis, 2015; 10:153; doi: 10.1186/s13023-015-0369-8
13.
ChiuHH, WuMH, ChenHC, et al.Epidemiological profile of Marfan syndrome in a general population: A national database study. Mayo Clin Proc, 2014; 89:34–42; doi: 10.1016/j.mayocp.2013.08.022
14.
GizzoL, BlissG, PalatyC, et al.Caregiver perspectives on patient-focused drug development for Phelan-McDermid syndrome. Orphanet J Rare Dis, 2024; 19:134; doi: 10.1186/s13023-024-03141-w
15.
PerssonJ, Gyllencreutz CastellheimA, DellborgM, et al.Survival trends in children with tetralogy of Fallot in Sweden from 1970 to 2017. JAMA Netw Open, 2023; 6:e2314504; doi: 10.1001/jamanetworkopen.2023.14504
16.
WuMH, LuCW, ChenHC, et al.Arrhythmic burdens in patients with tetralogy of Fallot: A national database study. Heart Rhythm, 2015; 12:604–609; doi: 10.1016/j.hrthm.2014.11.026
ChapmanAB, DevuystO, EckardtKU, et al.; Conference Participants. Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int, 2015; 88:17–27; doi: 10.1038/ki.2015.59
19.
MeuriceT, BarryF, Touzet-RoumazeilleS, et al.The oral and maxillofacial manifestations of Stickler syndrome: A systematic review. J Stomatol Oral Maxillofac Surg, 2025; 126:102261; doi: 10.1016/j.jormas.2025.102261
20.
WangDD, GaoFJ, HuFY, et al.Mutation spectrum of stickler syndrome type I and genotype-phenotype analysis in East Asian population: A systematic review. BMC Med Genet, 2020; 21:27; doi: 10.1186/s12881-020-0963-z
21.
StoroniS, TreurnietS, MaugeriA, et al.Prevalence and hospital admissions in patients with osteogenesis imperfecta in the Netherlands: A nationwide registry study. Front Endocrinol (Lausanne), 2022; 13:869604; doi: 10.3389/fendo.2022.869604
22.
TosiLL, OetgenME, FloorMK, et al.Initial report of the osteogenesis imperfecta adult natural history initiative. Orphanet J Rare Dis, 2015; 10:146; doi: 10.1186/s13023-015-0362-2
23.
JohnsonAF, NguyenHT, VeitiaRA. Causes and effects of haploinsufficiency. Biol Rev Camb Philos Soc, 2019; 94:1774–1785; doi: 10.1111/brv.12527
24.
EvansEF, ShyrZA, TraynorBJ, et al.Therapeutic development approaches to treat haploinsufficiency diseases: Restoring protein levels. Drug Discov Today, 2024; 29:104201; doi: 10.1016/j.drudis.2024.104201
25.
GagnonKT, CoreyDR. Guidelines for experiments using antisense oligonucleotides and double-stranded RNAs. Nucleic Acid Ther, 2019; 29:116–122; doi: 10.1089/nat.2018.0772
26.
UhlénM, FagerbergL, HallströmBM, et al.Proteomics. Tissue-based map of the human proteome. Science, 2015; 347:1260419; doi: 10.1126/science.1260419
27.
JinH, ZhangC, ZwahlenM, et al.Systematic transcriptional analysis of human cell lines for gene expression landscape and tumor representation. Nat Commun, 2023; 14:5417; doi: 10.1038/s41467-023-41132-w
28.
TseV, ChacaltanaG, GutierrezM, et al.An intronic RNA element modulates Factor VIII exon-16 splicing. Nucleic Acids Res, 2024; 52:300–315; doi: 10.1093/nar/gkad1034
29.
ForrestARR, KawajiH, RehliM, et al.; FANTOM Consortium and the RIKEN PMI and CLST (DGT). A promoter-level mammalian expression atlas. Nature, 2014; 507:462–470; doi: 10.1038/nature13182
30.
MooreJE, PurcaroMJ, PrattHE, et al.; ENCODE Project Consortium. Expanded encyclopaedias of DNA elements in the human and mouse genomes. Nature, 2020; 583:699–710; doi: 10.1038/s41586-020-2493-4
31.
DreosR, AmbrosiniG, Cavin PérierR, et al.EPD and EPDnew, high-quality promoter resources in the next-generation sequencing era. Nucleic Acids Res, 2013; 41:D157–D164; doi: 10.1093/nar/gks1233
32.
PazI, KostiI, AresMJr, et al.RBPmap: A web server for mapping binding sites of RNA-binding proteins. Nucleic Acids Res, 2014; 42:W361–W367; doi: 10.1093/nar/gku406
33.
Van NostrandEL, PrattGA, ShishkinAA, et al.Robust transcriptome-wide discovery of RNA-binding protein binding sites with enhanced CLIP (eCLIP). Nat Methods, 2016; 13:508–514; doi: 10.1038/nmeth.3810
34.
HofmanCR, HuJ, BrylR, et al.Nuclear Argonaute: MiRNA complexes recognize target sequences within chromatin-associated RNA and silence gene expression. Nucleic Acids Res, 2025; 53:gkaf800; doi: 10.1093/nar/gkaf800
BennettCF, KrainerAR, ClevelandDW. Antisense oligonucleotide therapies for neurodegenerative diseases. Annu Rev Neurosci, 2019; 42:385–406; doi: 10.1146/annurev-neuro-070918-050501
37.
LimKH, HanZ, JeonHY, et al.Antisense oligonucleotide modulation of non-productive alternative splicing upregulates gene expression. Nat Commun, 2020; 11:3501; doi: 10.1038/s41467-020-17093-9
38.
HanZ, ChenC, ChristiansenA, et al.Antisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model of Dravet syndrome. Sci Transl Med, 2020; 12:eaaz6100; doi: 10.1126/scitranslmed.aaz6100
39.
Stoke Therapeutics, Inc. A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome. ClinicalTrials.gov identifier: NCT06872125. 2025. Available from: https://clinicaltrials.gov/study/NCT06872125#study-overview [Last accessed: August11, 2025].
40.
Aartsma-RusA, JansonAA, KamanWE, et al.Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients. Hum Mol Genet, 2003; 12:907–914; doi: 10.1093/hmg/ddg100
41.
DominskiZ, KoleR. Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides. Proc Natl Acad Sci U S A, 1993; 90:8673–8677; doi: 10.1073/pnas.90.18.8673
SinghNK, SinghNN, AndrophyEJ, et al.Splicing of a critical exon of human survival motor neuron is regulated by a unique silencer element located in the last intron. Mol Cell Biol, 2006; 26:1333–1346; doi: 10.1128/mcb.26.4.1333-1346.2006
44.
HuaY, VickersTA, OkunolaHL, et al.Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice. Am J Hum Genet, 2008; 82:834–848; doi: 10.1016/j.ajhg.2008.01.014
45.
CoreyDR. Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy. Nat Neurosci, 2017; 20:497–499; doi: 10.1038/nn.4508
46.
HacheM, SwobodaKJ, SethnaN, et al.Intrathecal injections in children with spinal muscular atrophy: Nusinersen clinical trial experience. J Child Neurol, 2016; 31:899–906; doi: 10.1177/0883073815627882
47.
FinkelRS, MercuriE, DarrasBT, et al.; ENDEAR Study Group. Nusinersen versus Sham control in infantile-onset spinal muscular atrophy. N Engl J Med, 2017; 377:1723–1732; doi: 10.1056/NEJMoa1702752
48.
WangET, SandbergR, LuoS, et al.Alternative isoform regulation in human tissue transcriptomes. Nature, 2008; 456:470–476; doi: 10.1038/nature07509
49.
HillmanRT, GreenRE, BrennerSE. An unappreciated role for RNA surveillance. Genome Biol, 2004; 5:R8; doi: 10.1186/gb-2004-5-2-r8
50.
WightmanB, HaI, RuvkunG. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell, 1993; 75:855–862; doi: 10.1016/0092-8674(93)90530-4
51.
LeeRC, FeinbaumRL, AmbrosV. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell, 1993; 75:843–854; doi: 10.1016/0092-8674(93)90529-y
52.
RuvkunG, WightmanB, HaI. The 20 years it took to recognize the importance of tiny RNAs. Cell, 2004; 116:S93–S96; doi: 10.1016/s0092-8674(04)00034-0
KrützfeldtJ, RajewskyN, BraichR, et al.Silencing of microRNAs in vivo with ‘antagomirs’. Nature, 2005; 438:685–689; doi: 10.1038/nature04303
57.
AggarwalG, BanerjeeS, JonesSA, et al.Antisense oligonucleotides targeting the miR-29b binding site in the GRN mRNA increase progranulin translation. J Biol Chem, 2023; 299:105475; doi: 10.1016/j.jbc.2023.105475
58.
CoreyDR. It is time to revisit miRNA therapeutics. Nucleic Acid Ther, 2025; 35:1–5; doi: 10.1089/nat.2024.0069
59.
WethmarK, SminkJJ, LeutzA. Upstream open reading frames: Molecular switches in (patho)physiology. Bioessays, 2010; 32:885–893; doi: 10.1002/bies.201000037
60.
LiangXH, ShenW, SunH, et al.Translation efficiency of mRNAs is increased by antisense oligonucleotides targeting upstream open reading frames. Nat Biotechnol, 2016; 34:875–880; doi: 10.1038/nbt.3589
61.
LiY, LiJ, WangJ, et al.Targeting 3′ and 5′ untranslated regions with antisense oligonucleotides to stabilize frataxin mRNA and increase protein expression. Nucleic Acids Res, 2021; 49:11560–11574; doi: 10.1093/nar/gkab954
62.
JohnsonKC, CoreyDR. RNAi in cell nuclei: Potential for a new layer of biological regulation and a new strategy for therapeutic discovery. Rna, 2023; 29:415–422; doi: 10.1261/rna.079500.122
63.
MatsuiM, CoreyDR. Non-coding RNAs as drug targets. Nat Rev Drug Discov, 2017; 16:167–179; doi: 10.1038/nrd.2016.117
64.
MatsuiM, SakuraiF, ElbashirS, et al.Activation of LDL receptor expression by small RNAs complementary to a noncoding transcript that overlaps the LDLR promoter. Chem Biol, 2010; 17:1344–1355; doi: 10.1016/j.chembiol.2010.10.009
65.
ChuY, YueX, YoungerST, et al.Involvement of argonaute proteins in gene silencing and activation by RNAs complementary to a non-coding transcript at the progesterone receptor promoter. Nucleic Acids Res, 2010; 38:7736–7748; doi: 10.1093/nar/gkq648
66.
LiLC, OkinoST, ZhaoH, et al.Small dsRNAs induce transcriptional activation in human cells. Proc Natl Acad Sci U S A, 2006; 103:17337–17342; doi: 10.1073/pnas.0607015103
67.
JanowskiBA, YoungerST, HardyDB, et al.Activating gene expression in mammalian cells with promoter-targeted duplex RNAs. Nat Chem Biol, 2007; 3:166–173; doi: 10.1038/nchembio860
68.
SchwartzJC, YoungerST, NguyenNB, et al.Antisense transcripts are targets for activating small RNAs. Nat Struct Mol Biol, 2008; 15:842–848; doi: 10.1038/nsmb.1444
69.
MengL, WardAJ, ChunS, et al.Towards a therapy for Angelman syndrome by targeting a long non-coding RNA. Nature, 2015; 518:409–412; doi: 10.1038/nature13975
70.
BelgradJ, McConnellE, LeonardS, et al.The N=1 Collaborative: Advancing customized nucleic acid therapies through collaboration and data sharing. Nucleic Acids Res, 2025; 53:gkaf346; doi: 10.1093/nar/gkaf346
71.
CrookeST. Addressing the needs of patients with ultra-rare mutations one patient at a time: The n-lorem approach. Nucleic Acid Ther, 2022; 32:95–100; doi: 10.1089/nat.2021.0046
72.
Kim-McManusO, GleesonJG, MignonL, et al.A framework for N-of-1 trials of individualized gene-targeted therapies for genetic diseases. Nat Commun, 2024; 15:9802; doi: 10.1038/s41467-024-54077-5
73.
MeansJC, Martinez-BengocheaAL, LouiselleDA, et al.Rapid and scalable personalized ASO screening in patient-derived organoids. Nature, 2025; 638:237–243; doi: 10.1038/s41586-024-08462-1
